A novel protein tyrosine phosphatase 1B (PTP1B) inhibitor, FYGL, extracted from Ganoderma lucidum, was first reported to have an efficient hypoglycemic effect and high safety in vivo in our previous study.
Introduction
The protein tyrosine phosphatase 1B (PTP1B), a member of the protein tyrosine phosphatase (PTPs) family, is overexpressed in insulin-sensitive peripheral tissues, such as liver and muscle tissues, in type 2 diabetes mellitus (T2DM) patients; it negatively regulates the insulin signaling pathway by dephosphorylating insulin receptor substrate (IRS) on tyrosine residues.
1,2
Inhibiting PTP1B activity is considered an efficient strategy for the management of T2DM. Therefore, identifying PTP1B inhibitors is a topic of current interest; however, no ideal inhibitor has been found for clinical use thus far, because of either poor bioavailability or low safety.
3,4 Interestingly, our previous study found a novel PTP1B inhibitor, FYGL, which was extracted from Ganderma lucidum, a well-known Chinese medicinal fungus that has long been used as a traditional Chinese medicine. 5, 6 The molecular weight of FYGL is 2.6 Â 10 5 , and the structure of the dominant component is shown in Fig. 1 . FYGL is an amphiphilic hyperbranched proteoglycan consisting of hydrophilic polysaccharides (4 saccharide units) and lipophilic protein moieties (17 amino acids) with a ratio of 77 : 17 for saccharide : protein. 7 We rst demonstrated that FYGL has an efficient hypoglycemic effect and high safety in vivo, 5 but mechanism was still unclear. In order to understand the possible functional mechanism of FYGL, it is necessary to rst reveal how the biomacromolecule works at the cellular level. Therefore, herein, we focused on demonstrating the cell internalization and endocytosis mechanism of FYGL in HepG2 cells, which are engaged in glycogen synthesis.
Cell internalization of a macromolecular drug involves specic or multiple endocytosis processes. 8 Endocytosis is a process involving the uptake of particles, uids and macromolecules from the outside to the inside of a cell. 9 The endocytosis mechanisms mainly include clathrin-mediated endocytosis (CME) and clathrin-independent endocytosis (CIE); the latter involves caveolae/lipid-mediated endocytosis and macropinocytosis.
9 Endocytic pathways are key to current drug delivery strategies and functional materials used in the eld of biomedicine.
10 Macropinocytosis was rst observed in 1931, representing a distinct endocytic pathway in mammalian cell lines, 11, 12 and can contribute to the efficiency by which numerous cell-penetrating peptides translocate to the cytoplasm. 13 This process is an actin-dependent endocytic pathway and occurs through large vesicles of variable sizes (diameter 0.2-5 mm) called macropinosomes.
14 As a typical macropinocytosis tracer, dextran is oen used to co-localize with the studied drug in cells for proving the macropinocytosis mechanism. 15 A protein tyrosine kinase implicated in cancer and some intracellular signaling cascades, 16 c-sarcomagene (c-Src), can promote cell proliferation and inhibit cell apoptosis via PI3K/ Akt cascades. 17 In the initial stage of macropinocytosis, c-Src induces cell ruffling and inuences the cell shape, following which it closes the outermost margin to form a vesicle.
18
Pharmacologically selective inhibitors are generally used to study the mechanism of endocytosis.
9 Among the inhibitors, chlorpromazine can inhibit clathrin-mediated endocytosis but not specically during the process. 19 Nystatin can decompose cholesterol, and thus inhibit caveolae/lipid-mediated endocytosis. 20 Amiloride negatively inuences macropinocytosis.
21
Genistein mediates some kinases involved in endocytosis, 22 and LY294002 is a common inhibitor of phosphatidylinositol-3 kinase (PI3K), which regulates macropinocytosis and RhoAmediated endocytosis, a member of the Ras homolog gene family.
23
In the present study, we attempt to reveal the specic endocytosis process through which FYGL enters the HepG2 cells, for drug uptake. A clear understanding of the endocytosis mechanism of FYGL at the cellular level will shed light on the roles of traditional natural macromolecular products in medicine.
Materials and methods

Materials
FYGL was extracted from Ganderma lucidum in our laboratory. 
where C O is the original concentration of FYGL in phase-O, V O is the volume of phase-O, C W is the equilibrium concentration of FYGL in phase-W, and V W is the volume of phase-W.
Measurement of FYGL particle size
A solution of FYGL (2 mg mL À1 ) was prepared in phosphate buffered solution (PBS), and the particle size measured by Zetasizer Nano (Malvern, UK).
Cell culture
HepG2 cells were cultured in DMEM supplement with 10% FBS and 1% penicillin-streptomycin at 37 C, in 5% CO 2 atmosphere. 
CCK-8 test
HepG2 cells were seeded into 96-well plates, and then endocytic selective inhibitors (with different concentrations in DMEM with 2% FBS) were added into the wells and incubated for 4.5 h at 37 C. CCK-8 was added and cultured for another 0.5-2 h.
Each sample was replicated in three wells. Finally the optical density (OD) was measured at 450 nm by a microplate reader (Bio-Tek, USA) and the cell viability was calculated.
Intracellular uptake of FYGL
FYGL was labeled by a green uorescence marker, FITC, to form FITC-FYGL by the following procedure. FITC (1 mg) was dissolved in 1 mL DMSO, and the solution was added into sodium buffer containing 1 mg mL À1 FYGL at a volume ratio of 1 to 10.
This mixture was stirred for 24 h at 4 C, away from light, to form the FITC-FYGL solution. HepG2 cells were transferred into 12-well plates and incubated with the FITC-FYGL solution for 6 h, then washed with PBS, xed with 4% paraformaldehyde, permeated with 0.2% Triton X-100/PBS, and stained with DAPI for the cellular nucleus and rhodamine-phalloidin for the cytoskeleton. The HepG2 cells were nally mounted on the glass slide for observation of the uptake of FYGL in by a confocal laser scanning microscope (C2+, Nikon, Japan). In addition, the HepG2 cells were also transferred into 6-well plates at a density of 5 Â 10 5 to 1 Â 10 6 cells per well and incubated with FITC-FYGL at different concentrations for 6 h; the cell suspensions were then analyzed by ow cytometry (Gallios, Beckman coulter, USA) at channel FL1 (excitation wavelength at 488 nm and emission wavelength at 525 nm) to demonstrate the absorption of FYGL by the HepG2 cells.
Endocytic inhibition of FYGL in HepG2 cells
HepG2 cells were transferred into 6-well plates with a density of 5 Â 10 5 to 1 Â 10 6 cells per well, pre-incubated with endocytic selective inhibitors at safe concentrations for 0.5 h, and then incubated with FITC-FYGL at the indicated concentration for 4 h. Finally, the cell suspensions were analyzed by ow cytometry at channel FL1 and observed by confocal laser scanning microscope with the same protocol as described in part 2.6.
FYGL in HepG2 cells transfected by c-Src siRNA
HepG2 cells were seeded into 6-well plates. A mixture solution of 20 mM c-Src siRNA (synthesized by Sangon Bio. Co, sequence shown in Table 1 ) and 5 mL lipofectamine 6000 were premixed in opti-MEM and added into the wells. The solution was removed 6 h later and the cells were washed thrice with PBS. A solution of FITC-FYGL at the indicated concentration in DMEM with 2% FBS was added into the wells and incubated for 4 h at 37 C, followed by analysis of FCM and confocal laser scanning microscopy.
c-Src protein extraction and Western blot
HepG2 cells were lysed in RIPA lysis buffer (Beyotime Co. Ltd) and claried by centrifugation (12 000 Â g, 10 min, 4 C). The cell lysates were separated by 8% SDS-PAGE, transferred to a polyvinylidene uoride (PVDF) membrane, and then immunoblotted with rabbit polyclonal c-Src antibody (Sangon Co, Shanghai, China) and secondary goat anti-rabbit antibody (Cell Signaling Technology, USA). Bands were visualized with enhanced chemiluminescence solution (ECL, Biotanon) and detected by Image Lab camera (Bio-Rad, Germany); they were then quantied by densitometry scanning by the Image J soware.
Intracellular co-localization of FYGL and dextran
HepG2 cells were seeded at a density of 2 Â 10 4 cells per well; to these cells 100 mg mL À1 FITC-FYGL was added and incubated for 4 h. Following this, the medium was removed, TRITC-dextran was added and incubated for 10 min, and then the cells were xed with 4% paraformaldehyde and observed by a confocal laser scanning microscope.
Statistical analysis
All data were presented as mean AE SD. One-way ANOVA test was performed to analyze the statistical signicance between the two groups. A difference is considered to be statistically signicant when the p value was <0.05.
Results and discussion
Oil/water (O/W) partition coefficient of FYGL
A working drug should possess amphiphilic properties in order to be transported in the human body and penetrate into the cell membrane. The oil/water partition coefficient is an important Table 1 The c-Src siRNA sequence Fig. 2 The particle size distribution of FYGL in water at room temperature. Data are presented as mean AE SD (n ¼ 3).
index for the amphiphilic property of a compound. The equilibrium concentration of FYGL in phase-W was obtained according to the standard curve plotted by the BCA assay. The partition coefficient K OW of FYGL, calculated from eqn (1), was 1.29 AE 0.08, larger than 1.0, suggesting that FYGL is soluble in lipids to some extent, in addition to water. It is thus possibly capable of penetrating through cell membranes and entering cells, 25 and the structure of hydrophilic polysaccharide and lipophilic protein moieties including 17 amino acid residuals play an important role in cell penetration, especially the side chain of particular serine/threonine or tyrosine residues which are related to phosphorylation. Fig. 2 shows the particle size distribution of FYGL in water at room temperature. The particle size of FYGL is mainly distributed in the range 400-1000 nm, and polydispersity index (PDI) is 0.57 AE 0.03, suggesting that FYGL exists as aggregated particles in aqueous solution. Thus, the uptake of FYGL in cells maybe based on the mechanism of macropinocytosis in which the macropinocytic vesicles can endocytose the particles in the size range 200-5000 nm. (Fig. 3A) ; the uorescent intensity signicantly increased in a dose-dependent manner (Fig. 3B) . The confocal laser scanning microscopy images in Fig. 3C depict the intracellular uptake of FITC-FYGL in HepG2 cells.
The safe concentrations of FITC-FYGL and endocytic selective inhibitors in HepG2 cells
In order to investigate the endocytic mechanism, the safety of FITC-FYGL and the applied endocytic selective inhibitors for cells is necessary. The safety of FITC-FYGL and the selective inhibitors, genistein, amiloride, chlorpromazine, nystatin and LY294002, for HepG2 cells was tested using CCK-8. From Fig. 4 , it is found that FITC-FYGL is safe for HepG2 cells in a wide concentration range; even at concentrations higher than 300 mg mL À1 , the cell is still viable up to 85%. The safety of the applied endocytic inhibitors was also tested (data not shown). Table 2 lists the safe concentrations of FITC-FYGL and the applied endocytic selective inhibitors in HepG2 cells, which will be used in the subsequent experiments.
Inuence of endocytic selective inhibitors on FYGL uptake in HepG2 cells
Fig . 5A shows the FCM data of HepG2 cells (blank), the cells incubated with 100 mg mL À1 FITC-FYGL (control), and 100 mg mL À1 FITC-FYGL addition to preincubated 50 mg mL À1 chlorpromazine, 50 mg mL À1 nystatin, 100 mg mL À1 amiloride, 10 mg mL À1 LY294002, and 500 mg mL À1 genistein. From Fig. 5B , the uorescence at l ¼ 488 nm was referred to that of blank group, and the FITC-FYGL uorescence at l ¼ 488 nm in control group was normalized to 100. It was found that neither chlorpromazine nor nystatin had a signicant inhibitory effect on endocytosis of FYGL, so the possibilities of clathrin-mediated endocytosis and caveolae/lipid-mediated endocytosis are excluded. However, the FITC-FYGL uorescence in the groups with selective inhibitors of amiloride, LY294002 and genistein were all remarkably attenuated to different extents, compared with that in the control group, indicating that the uptake of FITC-FYGL in the cells was inhibited by amiloride, LY294002 and genistein. The results were also demonstrated by confocal laser scanning microscopy ( Fig. 5C ), which revealed that almost no green FITC-FYGL was observed in the cells with those inhibitors. Amiloride was reported to specically inhibit macropinocytosis by lowering the submembraneous pH; 27 herein, the signicant inhibition of the endocytic process of FYGL by amiloride indicated that the cellular uptake of FYGL was regulated by macropinocytosis. Macropinocytosis requires several kinases to activate numerous signaling pathways, which coordinate the formation of a macropinosome. 28 Genistein can inhibit either tyrosine kinases or caveolae pinching to regulate endocytosis.
22
In this study, the caveolae/lipid-mediated endocytosis of FYGL was excluded because nystatin did not inhibit FYGL entering the cells (Fig. 5) ; thus genistein may work on the inhibition of tyrosine kinase activity to block the uptake of FYGL.
As a quercetin analogue, LY294002 is widely used to specifically inhibit PI3K activity and macropinosome formation. 29, 30 PI3K activity in the process of membrane ruffling affects the formation of macropinosomes and phagosomes, especially the closure of ruffles and pseudopodia, in addition to the inuence on the roles of insulin and insulin growth factor-1 in signal transduction. [31] [32] [33] Herein, LY294002 down-regulated the uptake of FYGL in HepG2 cells, indicating that the uptake process might involve the PI3K cascade.
Endocytosis of FYGL mediated by c-Src protein
c-Src is a non-receptor tyrosine kinase and the upstream protein of PI3K, modulating ruffling in the early stages of phagocytosis. 18, 34, 35 Thus, inhibition of c-Src activity blocks the macropinocytosis process. 33 From Fig. 6A , HepG2 cells transfected with siRNA inhibited the expression of c-Src to a remarkable extent, compared with control group. The uptake of FYGL in HepG2 cells was also attenuated, which was demonstrated by FCM and the confocal laser scanning microscopy images in Fig. 6B-D . The results indicate that the endocytosis of FYGL in HepG2 cells is possibly on the c-Src/PI3K cascade involved in the macropinocytosis process.
Intracellular co-localization of FYGL and dextran
Dextran is used as a macropinocytosis tracer in endocytosis mechanism research. 15 The method of co-localization was used to prove that FYGL and dextran enter the cell via the same endocytosis pathway, if both compounds are overlaid in the cell. From the images in Fig. 7 , we can observe that when FYGL and dextran were cultured in HepG2 cells, they were co-localized in the cells, and the merged image of FYGL (green, FITC labelled) and dextran (red, TRITC labelled) showed orange cells. The results demonstrated again that the uptake of FYGL in HepG2 cells was mainly through macropinocytosis and also identied the result of Fig. 3C . 
Conclusions
In conclusion, we demonstrated that FYGL in aqueous solutions existed as aggregates with particle sizes in the range 400-1000 nm, and could be absorbed by HepG2 cells via the macropinocytosis mechanism. Moreover, we excluded clathrin-mediated endocytosis and caveolae/lipid-mediated endocytosis of FYGL by the pharmacologically selective inhibitor approach and proved that macropinocytosis mediated by c-Src/PI3K cascades was the preferred endocytic route. FYGL is a multidomain peptide that contains a polysaccharide and peptide domain and can potentially play multiple roles in the treatment of diseases. The specic structure of FYGL is an ideal case of bottom-up design where the modulation of chemical structure leads to controlled selfassembly and nanostructure, and eventually control of biological functions. 36 Our study provided the uptake basis of FYGL for efficient hypoglycemic action. The functional mechanism of the signaling pathway in vivo will be reported in the future.
